| Literature DB >> 31209353 |
Keith Jendza1, Mitsunori Kato1, Michael Salcius2, Honnappa Srinivas3, Andrea De Erkenez4, Anh Nguyen4, Doug McLaughlin2, Celine Be3, Christian Wiesmann3, Jason Murphy2, Philippe Bolduc1, Muneto Mogi1, Jose Duca1, Abdel Namil1, Michael Capparelli1, Veronique Darsigny1, Erik Meredith1, Ritesh Tichkule1, Luciana Ferrara4, Jessica Heyder4, Fang Liu4, Patricia A Horton2, Michael J Romanowski2, Markus Schirle2, Nello Mainolfi1, Karen Anderson4, Gregory A Michaud5.
Abstract
The complement pathway is an important part of the immune system, and uncontrolled activation is implicated in many diseases. The human complement component 5 protein (C5) is a validated drug target within the complement pathway, as an anti-C5 antibody (Soliris) is an approved therapy for paroxysmal nocturnal hemoglobinuria. Here, we report the identification, optimization and mechanism of action for the first small-molecule inhibitor of C5 complement protein.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31209353 DOI： 10.1038/s41589-019-0303-9
Source DB: PubMed Journal: Nat Chem Biol ISSN： 1552-4450 Impact factor: 15.040